GILD vs PATH
Gilead Sciences Inc (GILD) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the GILD and PATH stock pages for the full models.
Not investment advice.